Congress Finally Addresses Menopause: A New Era?

The Senate Special Committee on Aging convened its inaugural hearing on menopause on September 16, 2026, highlighting critical deficiencies in research, physician education, and patient care. This landmark session, aptly titled 'Half the Country, Zero Hearings,' underscored the belated attention menopause is receiving from federal bodies.

Following the hearing, Senators Kirsten Gillibrand and Rick Scott initiated a bipartisan request for the Government Accountability Office to scrutinize federal agency coordination and funding for menopause research. This action aligns with a broader legislative effort.

Sens. Patty Murray and Lisa Murkowski reintroduced the Advancing Menopause Care and Mid-Life Women's Health Act, a proposal authorizing $275 million over five years. This legislation aims to enhance NIH research with $25 million annually, alongside funding for clinician training and public health initiatives.

Comparative funding figures reveal a significant disparity, with NIH estimating $78 million for menopause research in fiscal 2025, substantially less than the $314 million allocated for prostate cancer research. This contrasts with the proposed dedicated research funding.

Addressing these foundational issues is crucial, as the medical system's understanding and organization lag behind the widespread public conversation and lived experience of menopause. Inadequate physician education on menopause further complicates the translation of research findings into clinical practice.

Simultaneously, public discourse on menopause has rapidly evolved, influenced by updated guidance on hormone therapy. In February 2026, the FDA revised labeling for hormone therapy products, removing broad warnings about cardiovascular disease and dementia, acknowledging that previous research, like the Women's Health Initiative, involved older participants and that risks are more nuanced.